X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8548) 8548
Book Review (2366) 2366
Publication (820) 820
Book Chapter (61) 61
Conference Proceeding (32) 32
Magazine Article (8) 8
Dissertation (6) 6
Reference (5) 5
Book / eBook (1) 1
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7453) 7453
humans (4993) 4993
glucagon-like peptide-1 (4693) 4693
animals (4030) 4030
male (3669) 3669
endocrinology & metabolism (2983) 2983
diabetes (2190) 2190
glucose (2180) 2180
female (2051) 2051
type 2 diabetes (2030) 2030
glucagon (1980) 1980
insulin (1917) 1917
diabetes mellitus, type 2 - drug therapy (1912) 1912
rats (1663) 1663
glucagon-like peptide 1 (1606) 1606
peptides (1598) 1598
mice (1535) 1535
glp-1 (1510) 1510
hypoglycemic agents - therapeutic use (1312) 1312
blood glucose - metabolism (1303) 1303
pharmacology & pharmacy (1293) 1293
obesity (1291) 1291
middle aged (1276) 1276
adult (1231) 1231
insulin - blood (1018) 1018
insulin - metabolism (978) 978
liraglutide (960) 960
glucagon-like peptide 1 - metabolism (954) 954
secretion (951) 951
physiological aspects (949) 949
abridged index medicus (941) 941
dextrose (932) 932
research (917) 917
analysis (892) 892
glycemic control (872) 872
diabetes mellitus (870) 870
rodents (823) 823
physiology (821) 821
food-intake (809) 809
glucagon-like peptide-1 receptor (793) 793
glucagon-like peptide 1 - blood (780) 780
hypoglycemic agents - administration & dosage (773) 773
diabetes mellitus, type 2 - blood (759) 759
insulin secretion (754) 754
glucagon-like peptide 1 - analogs & derivatives (751) 751
insulin resistance (733) 733
aged (723) 723
hypoglycemic agents - pharmacology (721) 721
exenatide (712) 712
health aspects (707) 707
blood glucose - drug effects (704) 704
diabetes mellitus, type 2 - metabolism (680) 680
digestive, oral, and skin physiology (659) 659
care and treatment (657) 657
internal medicine (655) 655
metabolism (653) 653
treatment outcome (649) 649
medicine & public health (633) 633
peptides - pharmacology (632) 632
glucose metabolism (630) 630
nutrition & dietetics (611) 611
rats, sprague-dawley (589) 589
type-2 diabetes-mellitus (584) 584
beta-cell function (577) 577
mice, inbred c57bl (576) 576
biochemistry & molecular biology (575) 575
glucagon-like peptide 1 - therapeutic use (573) 573
hormones (562) 562
hyperglycemia (556) 556
hypoglycemic agents (555) 555
insulin-secretion (547) 547
endocrine system (545) 545
body weight (544) 544
glucagon-like peptide 1 - pharmacology (534) 534
drug therapy (533) 533
glucose tolerance test (529) 529
gastric-inhibitory polypeptide (519) 519
exendin-4 (518) 518
hypoglycemic agents - adverse effects (515) 515
expression (512) 512
metformin (511) 511
double-blind (508) 508
article (501) 501
diabetes therapy (498) 498
risk factors (496) 496
glucose - metabolism (491) 491
incretin (491) 491
peptides - therapeutic use (491) 491
receptor (486) 486
glucagon-like peptide 1 - administration & dosage (478) 478
hormones, hormone substitutes, and hormone antagonists (472) 472
dose-response relationship, drug (463) 463
neurosciences (463) 463
dipeptidyl-peptidase iv inhibitors - therapeutic use (459) 459
blood glucose - analysis (455) 455
body-weight (446) 446
receptors, glucagon - agonists (432) 432
glucagon - blood (430) 430
homeostasis (426) 426
venoms - pharmacology (422) 422
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8478) 8478
German (31) 31
Japanese (16) 16
French (15) 15
Chinese (9) 9
Spanish (8) 8
Czech (7) 7
Danish (6) 6
Russian (3) 3
Swedish (3) 3
Korean (2) 2
Polish (2) 2
Bosnian (1) 1
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2015, Volume 58, Issue 18, pp. 7370 - 7380
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9861, pp. 117 - 124
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 11 - 22
Journal Article
by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 04/2012, Volume 32, Issue 14, pp. 4812 - 4820
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 642 - 649
Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. Methods In... 
metformin | GLP | receptor | type 2 diabetes | pharmacodynamics | Type 2 diabetes | Pharmacodynamics | GLP-1 | Metformin | Receptor | FASTING PLASMA-GLUCOSE | GLYCEMIC CONTROL | SAFETY | EXENATIDE | OPEN-LABEL | PEPTIDE-1 ANALOG | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | DOUBLE-BLIND | GLP-1 RECEPTOR AGONIST | PLACEBO-CONTROLLED TRIAL | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | C-Peptide - blood | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Glucagon - blood | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Hyperinsulinism - prevention & control | Glucagon-Like Peptide 1 - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Care and treatment | Glucagon | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus | Original
Journal Article